• Mackenzie Duncan Gregory Caulfield, Rupinder Brar, Christy Sutherland, and Seonaid Nolan.
• Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada.
• BMJ Case Rep. 2020 Mar 25; 13 (3).

AbstractIn the wake of North America's opioid crisis, access to evidence-based treatment for opioid use disorder (OUD) is of critical importance. While buprenorphine/naloxone and methadone are currently indicated as first-line medications for the treatment of OUD, there are a proportion of individuals who do not benefit from these therapies. Recent Canadian guidelines suggest the use of alternate therapies, including slow-release oral morphine or injectable opioid agonist therapy (iOAT) for individuals unsuccessful with either methadone or buprenorphine/naloxone. While the guidelines highlight the need to intensify OUD treatment as disease severity increases, equally important is the consideration for deintensification of treatment (eg, from iOAT to an oral opioid agonist treatment (OAT) option) following successful stabilisation. Literature addressing how best to accomplish this, however, is currently lacking. Accordingly, the case presented here describes a patient that successfully transitions from iOAT to oral buprenorphine/naloxone using a novel induction approach termed microdosing.© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

21 keywords...

hide…